Login Preferences
About News Publications Statistics Downloads API Guide License How to use Preferences
bn:00046690n
Noun Concept
Categories: Janssen Pharmaceutica, Drugs that are a monoclonal antibody, Schering-Plough brands, World Health Organization essential medicines, Immunosuppressants
EN
infliximab  Remicade  ATC code L04AB02  ATCvet code QL04AB02  Avsola
EN
An anti-TNF compound (trade name Remicade) consisting of an antibody directed against TNF; it is given intravenously at one-month to three-month intervals; used in treatment of regional enteritis and rheumatoid arthritis WordNet 3.0
Definitions
Relations
Sources
EN
An anti-TNF compound (trade name Remicade) consisting of an antibody directed against TNF; it is given intravenously at one-month to three-month intervals; used in treatment of regional enteritis and rheumatoid arthritis WordNet 3.0 & Open English WordNet
Infliximab, a chimeric monoclonal antibody, sold under the brand name Remicade among others, is a medication used to treat a number of autoimmune diseases. Wikipedia
Pharmaceutical drug Wikidata
IS A
anti-TNF compound
compound
medicine
monoclonal antibody
biopharmaceutical
MEDICAL CONDITION TREATED
ankylosing spondylitis
arthritis
colitis
irritable bowel syndrome
Kawasaki disease
+7 relations
PREGNANCY CATEGORY
Australian pregnancy category C
ROUTE OF ADMINISTRATION
intravenous drip
SUBJECT HAS ROLE
disease-modifying antirheumatic drug
dermatologic drug
USAGE DOMAIN
trade name
WordNet 3.0 & Open English WordNet
EN
infliximab, Remicade
Wikipedia
EN
infliximab
Wikidata
EN
infliximab
Wikipedia Redirections
EN
ATC code L04AB02, ATCvet code QL04AB02, Avsola, Flixabi, Infimab, infliximab-abda, infliximab-dyyb, Ixifi, Remicade, Remsima, Remsima SC, Renflexis, Zessly
Wikidata Alias
EN
cA2, CA2 ????, Ig gamma-1 chain C region

Please note that, in order to improve your browsing experience on this website, BabelNet® uses various types of cookies, including: browsing functionality, performance and statistical cookies.

By continuing to browse the site you are agreeing to our use of cookies. OK

License